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MitochondriaThere is an increasing need for novel preventive and therapeutic strategies to combat obesity and related meta-
bolic disorders. In this respect, the natural polyphenol resveratrol has attracted signiﬁcant interest. Animal stud-
ies indicate that resveratrol mimics the effects of calorie restriction via activation of sirtuin 1 (SIRT1). SIRT1 is an
important player in the regulation of cellular energy homeostasis and mitochondrial biogenesis. Rodent studies
have shown beneﬁcial effects of resveratrol supplementation on mitochondrial function, glucose metabolism,
body composition and liver fat accumulation. However, conﬁrmation of these beneﬁcial effects in humans by
placebo-controlled clinical trials remains relatively limited. This review will give an overview of pre-clinical
and clinical studies examining the effects of resveratrol on obesity-induced negative health outcomes. This article
is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical ﬁndings to improved patient
outcomes.
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The prevalence of obesity is increasing tremendously worldwide. A
recent systematic analysis for the Global Burden of Disease Study
reported a worldwide increase in overweight and obesity between
1980 and 2013 from 28.8% to 36.9% in men and 29.8% to 38.0% in
women [1]. Obesity presents a health risk, partly due to ectopic fat accu-
mulation; fat accumulation in non-adipose tissue such as liver and skel-
etal muscle. Accumulation of fat in the liver, when unrelated to alcohol
intake, is a strong independent marker of dyslipidaemia and insulin re-
sistance. Insulin resistance in turn predisposes to the development of
type 2 diabetes (T2D) [2–4]. Impaired mitochondrial function is also
often seen in obese and/or T2D patients [5]. Mitochondria play a central
role in energy homeostasis and substrate metabolism. Therefore, re-
duced mitochondrial function has substantial effects on glucose and
lipid metabolism, deteriorating metabolic health.
The rise in obesity prevalence is predominantly causedby changes in
lifestyle, such as decreased physical activity and increased intake of
energy-dense food. The primary solution for this obesity epidemic,
and its related negative effects on public health, should therefore also
be sought in changing lifestyle. Increasing the amount of physicalol: Challenges in translating pre-
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(P. Schrauwen).activity or decreasing energy intake are proven effective therapeutic
strategies to positively inﬂuence health outcomes related to obesity.
Correspondingly, restricting calorie intake for sixmonths leads to an im-
provement in insulin sensitivity [6], which in turn is accompanied by an
increase in muscle mitochondrial biogenesis [7]. However, people in
general have difﬁculties following strict exercise training or dieting
regimes. Alternative treatments are therefore highly sought after. This
has led to the search for compounds that can initiate beneﬁcial health
effects similar to those from exercise training or calorie restriction.
2. Resveratrol
Resveratrol (3, 5, 4′ trihydroxystilbene) is a polyphenol naturally
present in and produced by several plants. The richest source of natural
resveratrol is Polygonum cuspidatum, a plant known from traditional
Chinese and Japanese medicine [8]. Smaller amounts of resveratrol can
also be found in peanuts, grapes, red wine and mulberries [9]. In 2003,
Howitz et al. [9] identiﬁed resveratrol as a small-molecule activator of
sirtuin 1 (SIRT1). SIRT1, like all members of the sirtuin family, requires
nicotinamide adenine dinucleotide (NAD+) for its deacetylating activi-
ty [10]. The dependence of SIRT1 on NAD+ strongly links its activity to
cellular energy levels. SIRT1 is induced both by calorie restriction and
exercise [11] and plays an important role in the regulation of lipid and
glucose homeostasis [12]. The fact that SIRT1 is closely connected to cel-
lular energy levels and energy homeostasis makes it an interesting mo-
lecular target for treatment of metabolic disorders such as obesity.
Considering resveratrol has been identiﬁed as a small-molecule activa-
tor of SIRT1, it is not surprising that resveratrol has been said to have
calorie restriction-like effects [13–16]. However, there is debate
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vation of AMP-activated protein kinase (AMPK) [19,20]. AMPK and
SIRT1 both play a crucial role in energy homeostasis and their activity
is closely interrelated. It is therefore difﬁcult to identify whether resver-
atrol activates SIRT1 or AMPK or both, either direct or indirect. Recently,
Park et al. [21] proposed that the metabolic effects of resveratrol might
result from competitive inhibition of cAMP-degrading phosphodiester-
ases, leading to elevated cAMP levels. Consequently, through a cascade
of effects, this could lead to activation of AMPK, followed by an increase
in NAD+ andﬁnally an increase in SIRT1 activity [21]. Unfortunately, the
exact mechanism is still unknown. Despite the mechanism of action,
resveratrol is a promising candidate for treatment and prevention of
metabolic diseases by mimicking calorie restriction-like effects.
The aim of this review is to evaluate the potential effects of res-
veratrol on obesity-related health outcomes mainly in humans, both
in experimental and clinical settings (see Table 1 for an overview of
published peer-reviewed clinical trials on resveratrol and obesity-
related health outcomes). Studies that used grape extract containing
resveratrol or other formulas with multiple components are not taken
into account. The effects of resveratrol on mitochondrial function,
body composition, energy expenditure, insulin resistance and liver fat
accumulation will be evaluated.
3. Effects of resveratrol on muscle mitochondrial function
Excessive energy intake and a low level of physical activity will lead
to accumulation of fat in adipose tissue. In turn, this excessive fat accu-
mulation can lead to lipid overﬂow and accumulation of fat in non-
adipose tissue, such as the liver and skeletal muscle [22,23]. In general,
muscle fat accumulation correlates negatively with insulin sensitivity
[24] especiallywhenmitochondrial fat oxidative capacity is low. Indeed,
T2Dpatients and people at high risk of developing T2D are characterised
by high intramyocellular lipid levels and a decreased mitochondrial
fatty acid oxidative capacity [25,26]. Peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC-1α) is a crucial regulator of
mitochondrial metabolism and biogenesis, and a downstream effector
of theAMPK-SIRT1 signalling pathway [27]. Several studies have report-
ed a reduction in PGC-1α gene expression in T2D patients [28,29]. This
disrupted gene expression pattern can also be seen in non-diabetic off-
spring of T2D patients [29]. It has been suggested that a low PGC-1α
gene expression can lead to reduced generation of mitochondrial
proteins, resulting in loss of mitochondrial capacity and decreased insu-
lin sensitivity [29]. Exercise training and calorie restriction are proven
effective strategies to improvemusclemitochondrial oxidative capacity,
paralleled by improvements in whole body insulin sensitivity [7,30,31].
Thus, six months of calorie restriction has been shown to increase ex-
pression of AMPK, PGC-1α and SIRT1, increasemitochondrial DNA con-
tent and reduce fasting insulin levels [7]. Therefore, improving muscle
oxidative capacity appears to be an effective strategy for counteracting
obesity-induced insulin resistance and T2D.
A couple of animal studies have actually investigated the effects
of resveratrol on muscle mitochondrial capacity. A rodent study by
Lagouge et al. [32] included four different intervention groups: male
C57BL/6J mice on a high-fat diet (HFD) with or without a dose of
400 mg/kg/day (mpk) of resveratrol or on a chow diet with or without
resveratrol (400 mpk). The intervention period was 15 weeks. They
found that mitochondria in non-oxidative muscle ﬁbres of resveratrol-
treated HFD mice were larger and denser, and mitochondrial DNA con-
tent increased compared with HFD animals that did not receive resver-
atrol. Um et al. [20], who also treated male C57BL/6J mice whilst on a
HFD with 400 mpk resveratrol, reported increased mitochondrial con-
tent (measured by cytochrome C protein levels and mitochondrial
DNA) comparedwith no resveratrol-treatment after an intervention pe-
riod of 13weeks. In addition, theymeasured a decrease in the content of
the fatty acid intermediates diacylglyceride and ceramide in skeletal
muscle. To further investigate mitochondrial activity, both studiesmeasured PGC-1α expression in skeletal muscle. PGC-1α mRNA [20,
32] and protein [32] signiﬁcantly increased in resveratrol-treated ani-
mals. Additionally, resveratrol treatment increased physical endurance
of mice, as evidenced by increased running time [20,32]. A recent
study by Price et al. [17], using two different doses of resveratrol (25–
30 mpk and 215–300 mpk), also found beneﬁcial effects of resveratrol
on mitochondrial biogenesis and function. The mice were fed a HFD of
a standard diet for eight months. The HFD led to signiﬁcantly impaired
function of mitochondria isolated from skeletal muscle. Supplementa-
tionwith either of the two resveratrol doses for eightmonths prevented
theHFD-inducedmitochondrial dysfunction. Thus, increasesweremea-
sured compared with HFD animals without resveratrol supplementa-
tion in: ADP-stimulated respiration (state 3), FCCP-induced maximal
oxidative respiration (state u), mitochondrial membrane potential,
and cellular ATP levels. These levelswere comparable tomice fed a stan-
dard diet. In addition, treatmentwith resveratrol resulted in a ﬁbre type
switch towards more oxidative muscle ﬁbre types, and prevented the
HFD-induced decline in mitochondrial content (measured by citrate
synthase activity and by mitochondrial DNA content). Interestingly,
when SIRT1 knockout mice were used none of the above-mentioned ef-
fects of resveratrol were observed. Moreover, SIRT1 overexpression re-
sulted in similar effects as resveratrol treatment in wild type mice. The
authors therefore concluded that SIRT1 plays a crucial role in improving
mitochondrial function by resveratrol supplementation (25–30 mpk).
Chen et al. [33] performed a study with male Sprague–Dawley rats fed
a normal diet, HFD or HFD with resveratrol (100 mpk by intragastric
administration) and found results comparable to Price et al. [17].
Hence, resveratrol-treatment increased SIRT1 activity andmitochondri-
al biogenesis, compared to a HFDwithout resveratrol. Furthermore, res-
veratrol reverted the decline in subsarcolemmal mitochondrial citrate
synthase and electron transport chain activities and decreased IMCL
content. Pearson et al. [34] investigated the effects of resveratrol on
muscle mitochondrial function in a non-obese animal model. One-
year old male C57BL/6NIA mice received a chow diet, both diets with
and without resveratrol added (~30.9 mpk). An additional group of
mice were fed every-other-day, which is a form of calorie restriction.
They concluded that resveratrol shifts muscle mitochondrial gene ex-
pression patterns in mice on a standard diet towards those on a calorie
restriction diet.
Together, these ﬁndings from animal studies indicate that res-
veratrol can inﬂuence mitochondrial biogenesis via activation of the
AMPK–SIRT1–PGC-1α axis. This has led to the generally accepted idea
that improving mitochondrial function by resveratrol supplementation
is a promising strategy for improvingmetabolic health in humans. In ac-
cordance with ﬁndings from rodent studies, we have demonstrated in a
previous clinical trial that resveratrol-treatment leads to activation of
AMPK, increases SIRT1 and PGC-1α protein levels and increases citrate
synthase activity [13]. Thus, Timmers et al. [13] studied 11 obese but
otherwise healthy males receiving a dose of 150 mg resveratrol or pla-
cebo per day for 30 days, in a double-blind cross over design. No differ-
ence was found in mitochondrial content, in contrast to animal studies
[20,32]. However, muscle mitochondrial fatty acid oxidative capacity
was improved on a fatty acid-derived substrate (state 3 respiration),
as determined by increased mitochondrial respiration. In contrast to
data from animal studies, IMCL content in the vastus lateralis muscle
was increased upon resveratrol-treatment. Combining the improve-
ment in muscle fat oxidative capacity, increased IMCL content and
other beneﬁcial metabolic adaptations found in this study, the hypoth-
esis emerged that resveratrol-treatment could have an endurance
training-like effect [14,30]. One other human intervention investigated
the effect of resveratrol on mitochondrial function, although indirectly
by examining gene expression pathways related to mitochondrial func-
tion [15]. Thus, Yoshino et al. [15] studied non-obese postmenopausal
womenwith normal glucose tolerance. Fifteenwomen received resver-
atrol (75 mg per day) and fourteen women received placebo, for a peri-
od of 12 weeks. Contradicting Timmers et al. [13], they concluded that
Table 1
Summary of peer-reviewed clinical trials in the ﬁeld of obesity.
Author, country
[ref]
Population (n) Design Dose of resveratrol Duration Objective Outcome
Bhatt et al., India [43] T2D men and women on oral
hypoglycemic treatment (57)
Randomised, prospective,
open-label control trial
250 mg once daily 3 mo Glycemic control and
associated risk factors
Resveratrol signiﬁcantly improved mean HbA1c, systolic blood pressure, total
cholesterol and total protein. No changes in body weight and high-density
lipoprotein and low-density lipoprotein cholesterol.
Brasnyo et al.,
Hungary [59]
T2D men on oral glucose
lowering medication (19)
Randomised, placebo-controlled,
double-blind parallel design
5 mg twice daily 4 wks Insulin sensitivity and
oxidative stress
Resveratrol signiﬁcantly decreased insulin resistance (measured by HOMA-IR)
and urinary ortho-tyrosine excretion (as a measure of oxidative stress), whilst
it increased the pAkt:Akt ratio in platelets.
Chachay et al.,
Australia [55]
Overweight/obese men with
NAFLD (20)
Randomised, placebo-
controlled parallel design
3000 mg once daily 8 wks Insulin resistance,
hepatic steatosis and
abdominal fat
distribution
Resveratrol did not reduce insulin resistance (measured by a hyperinsulinemic
euglycemic clamp), steatosis, or abdominal fat distribution. No change was
observed in plasma lipids or antioxidant activity. Levels of ALT and AST increased
signiﬁcantly among patients in the resveratrol group until week 6
Crandall et al., USA [44] Elderly men and women with
impaired glucose tolerance
(10)
Open-label study 1, 1.5 or 2 g once daily 4 wks Glucose metabolism
and vascular function
Resveratrol (1.5 and 2 g) decreased peak glucose and 3-h glucose AUC following
a meal, and improved Matsuda Index for insulin sensitivity. Weight, blood pressure
and lipids were unchanged. There was a trend towards improved postmeal
reactive hyperemia index
Dash et al., Canada [56] Overweight/obese men with
mild hypertriglycemia (8)
Randomised, placebo-controlled,
double-blind crossover study
1000 mg daily the ﬁrst
week, 2000 mg daily
the second week
2 wks Intestinal and hepatic
lipoprotein turnover
Resveratrol did not signiﬁcantly affect insulin sensitivity (measured by HOMA-IR),
fasting or fed plasma triglyceride concentration. Reduction apoB-48 production
without signiﬁcant effect on fractional catabolic rate. Resveratrol reduced apoB-100
and fractional catabolic rate.
Elliott et al. [58] T2D patients 2.5 or 5 g once daily 28 d Insulin sensitivity Resveratrol (5 g) decreased fasting and postprandial glucose and insulin
Magyar et al.,
Hungary [57]
Male and female patients with
stable coronary artery disease
(40)
Randomised, placebo-controlled,
double-blind trial
10 mg once daily 3 mo Cardioprotective
effects
Resveratrol improved left ventricle diastolic function, endothelial function,
lowered LDL-cholesterol level and protected against unfavourable
haemorheological changes. No signiﬁcant difference in HbA1c.
Movahed et al.,
Iran [46]
T2D men and women on oral
hypoglycemic treatment (66)
Randomised, placebo-controlled,
double-blinded parallel clinical
trial
500 mg twice daily 45 d Antihyperglycemic
effects
Resveratrol signiﬁcantly decreased systolic blood pressure, fasting blood glucose,
HbA1c, insulin, and insulin resistance (measured by HOMA-IR), whilst HDL was
signiﬁcantly increased. Liver and kidney function markers were unchanged
Poulsen et al.,
Denmark [45]
Healthy obese men (24) Randomised, placebo-controlled,
double-blind parallel design.
Resveratrol
500 mg thrice daily 4 wks Metabolic effects Resveratrol did not change insulin sensitivity (measured by a hyperinsulinemic
euglycemic clamp), blood pressure, resting energy expenditure, lipid oxidation
rates, ectopic or visceral fat content, or inﬂammatory or metabolic biomarkers
Timmers et al.,
The Netherlands [13]
Healthy obese men (11) Randomised, placebo-controlled,
double-blind crossover design
75 mg twice daily 30 d Metabolic effects Resveratrol improved metabolic proﬁle: resveratrol reduced sleeping and resting
metabolic rate. In muscle resveratrol activated the AMPK–SIRT1–PGC1α axis. A
reduction in blood glucose and insulin levels and liver. Improved muscle
mitochondrial function and reduced inﬂammation markers in the blood.
Yoshino et al.,
USA [15]
Nonobese postmenopausal
women with normal glucose
tolerance (29)
Randomised, placebo-controlled,
double-blind parallel design
75 mg once daily 12 wks Metabolic effects Resveratrol did not change resting metabolic rate, body composition, inﬂammatory
markers or plasma lipids. Resveratrol did not increase liver, skeletal muscle, or
adipose tissue insulin sensitivity (measured by a hyperinsulinemic euglycemic clamp).
Resveratrol did not affect AMPK, SIRT1, NAMPT, or PGC1α in either skeletal muscle or
adipose tissue.
ref, reference; T2D, type 2 diabetes mellitus; wks, weeks; mo, months; d, days; NAFLD, non-alcoholic fatty liver disease.
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SIRT1 gene expression in skeletal muscle. It must be noted that the
dose used by Timmers et al. [13] was double the dose that Yoshino
et al. [15] used. Furthermore, our trial included obese men, implying
that resveratrol could have beneﬁcial effects on people with compro-
mised health but not on healthy non-obese humans. Unfortunately, no
other data from human interventions are currently available regarding
the effect of resveratrol on muscle mitochondrial function.
4. Effect of resveratrol on body composition and energy expenditure
Rodent studies suggest that high doses of resveratrol (~400 mpk)
can lead to a reduction in weight gain when animals are fed a HFD
[32,35]. Two rodent studies by Lagouge et al. [32] and Kim et al. [35]
both used a similar set-up with male C57BL/BJ mice and a resveratrol
dose of 400 mpk. The study by Kim et al. [35] included three different
mice groups: HFD with or without resveratrol or chow diet without
resveratrol, with an intervention period of 10 weeks. Both studies
were consistent in reporting a blunting of body mass gain in the HFD–
resveratrol group compared with the HFD group. The blunted weight
gain was accounted for by a decrease in visceral fat-pad weights and
smaller adipocytes in epididymal adipose tissue [32,35]. The beneﬁcial
effect of resveratrol on body mass and composition could not be attrib-
uted to decreased food intake, since both resveratrol-treated and non-
resveratrol-treated animals consumed an equal amount of calories.
Lagouge et al. [32]measured energy expenditure of themice by indirect
calorimetry and recorded a higher basal energy expenditure (EE)
accompanied by a decrease in locomotor activity. This suggests that res-
veratrol had a stimulating effect on energy expenditure. The latter re-
sults are in accordance with those found in a non-human primate
model of obesity [36]. Six male grey mouse lemurs received a dose of
~200 mpk resveratrol for four weeks, during their winter body-mass
gain period. Supplementation of resveratrol led to an increase in resting
EE of 29% and a reduction in body-mass gain, comparedwith the control
period. Contrary to the rodent studies, the greymouse lemurs decreased
their food intake upon resveratrol-treatment, thereby contributing to
the decrease in weight gain. As a follow-up of this short-term non-
human primate study a larger group of animals received the supple-
ments (~200 mpk) for one year [37]. Overall, there were no differences
in bodyweight, food intake or physical activity between resveratrol and
control animals. Yet, at the beginning of the so-called long day period
(spring/summer period) an increase in fat free mass was noted in the
resveratrol-supplemented lemurs, which was accompanied by an in-
crease in total daily EE and resting EE. Overall, the ﬁndings from animal
studies suggest that resveratrol could stimulate energy expenditure and
protect against HFD-induced weight gain.
To further examine how resveratrol might increase energy expendi-
ture, Lagouge et al. [32] examined thermogenesis during a cold testwith
the focus on brown adipose tissue (BAT). In mice the main contributor
to heat production is BAT, which in contrast to white adipose tissue
stores little fat and burns fat to produce heat and regulate body temper-
ature; non-shivering thermogenesis [38]. It was found that mitochon-
dria were signiﬁcantly larger and also mitochondrial DNA content was
increased in BAT of resveratrol-treated mice [32]. These changes were
accompanied by an increase in gene expression of SIRT1, a decrease in
PGC-1α acetylation and an increase in PGC-1α activity. These ﬁndings
suggest that resveratrol may affect BAT metabolism. Accordingly, a sig-
niﬁcant increase in uncoupling protein 1 (UCP1) and SIRT1 gene expres-
sion in BAT was found in male mice treated with resveratrol for eight
weeks (400 mpk) [39] and in Sprague–Dawley rats treated for six
weeks (30 mpk) [40]. Also, gene expression of PGC-1α and peroxisome
proliferator-activated receptor β/δ (PPARβ/δ) was signiﬁcantly higher
in BAT of the resveratrol-supplemented rats. Bone Morphogenetic Pro-
tein 7 (BMP7) could also be involved in the effect of resveratrol on
BAT, since BMP7 is a crucial factor in brown adipogenesis and 2 months
of resveratrol-treatment (400 mpk) were shown to increase BMP7expression in BAT of mice [39]. Previous studies demonstrated that
BMP7 promotes brown pre-adipocyte differentiation [41]. In vitro treat-
ment of brown pre-adipocytes with BMP7 induced PGC-1α and in-
creased gene expression of UCP1 and PPARγ [41]. In addition, when
gene expression of BMP7 was stimulated in vivo, this resulted in a sig-
niﬁcant increase in BATmass accompanied by an increase in energy ex-
penditure and a reduction in weight gain [41]. Taken together, the data
illustrate that resveratrol, via activation of SIRT1, UCP1 and potentially
BMP7, could inﬂuence brown adipocyte differentiation. This in turn
could lead to increased energy expenditure and eventually weight
loss.Whether similar effects of resveratrol are present in humans unfor-
tunately remains unclear. It is difﬁcult to investigate molecular aspects
of BAT metabolism in humans since BAT is located in regions of the
human body that are difﬁcult to reach. However, future human studies
could investigate the effect of resveratrol on BAT activity using PET-CT
scanning [42].
So far, no effect of resveratrol has been found in human trials
concerning body weight [13,15,43–46] or body composition [15,45].
It is however important to note that in the human studies performed
so far, participants were generally instructed to consume their usual
diet and were not challenged with a HFD or high-calorie diet (HCD) in
contrast to the animal studies. Moreover, in human interventions,
relatively low doses of resveratrol have been used ranging from 75 to
2000 mg/d. In that respect, it is interesting to mention that also in ro-
dents a relatively low dose of resveratrol (~22.4 mpk) does not lead to
a decrease in body weight [19]. In addition, the possibility cannot be
excluded that metabolism of resveratrol differs between humans and
animals. The duration of the resveratrol supplementation could also
have been too short in the human intervention studies performed
so far. Strikingly, we have previously demonstrated that 30 days of
resveratrol supplementation (150 mg/day) leads to a reduction in
energy expenditure in healthy obese males [13]. Thus, in sharp contrast
to animal studies, resveratrol supplementation resulted in a lower
sleepingmetabolic rate as well as a lower postprandial energy expendi-
ture [13]. Long-term studies in humans are needed to provide deﬁnitive
answers as to whether resveratrol can affect energy expenditure or
body composition in humans.
5. Effects of resveratrol on insulin sensitivity
Obesity is one of the major determinants of insulin resistance and
T2D. As described earlier in this review, improvingmuscle oxidative ca-
pacity can counteract obesity-induced insulin resistance [30]. Rodent
studies have demonstrated that resveratrol can have beneﬁcial effects
on glucose homeostasis in animal models of obesity, diabetes and met-
abolic dysfunction [19,20,32,35,47–52]. These studies used variable
doses of resveratrol, ranging from 2.5 to 400mpk. In addition, the expo-
sition time also varied from between 2 weeks and 16 months. Lagouge
et al. [32] investigated mice on a HFD with or without resveratrol sup-
plementation (400mpk) for 15 weeks. A signiﬁcant reduction in fasting
insulin levels was found in resveratrol-treated animals, compared with
HFD animals without resveratrol supplementation. This decrease in
insulin was not accompanied by alterations in fasting glucose levels. In
addition, insulin sensitivity was assessed by the hyperinsulinemic
euglycemic clamp technique, which is regarded as the gold standard
for measuring insulin sensitivity. Improved insulin sensitivity was
found in the resveratrol group compared with the HFD group without
resveratrol. Shang et al. [48] also used the hyperinsulinemic euglycemic
clamp technique to determine insulin sensitivity. Resveratrol treat-
ment (100 mpk for 10 weeks) in HFD-fed male Wistar rats resulted
in a higher glucose infusion rate accompanied by reduced fasting
plasma insulin levels, compared with HFD animals that did not receive
resveratrol. Sun et al. [52] used a relatively low dose of resveratrol,
namely 2.5 mpk for 16 weeks, and found that resveratrol treatment
signiﬁcantly improved glucose tolerance (as determined by a glucose
tolerance test) in HFD-fed male C57BL/6J mice with glucose disposal
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resveratrol administration also considerably improved insulin sensitiv-
ity as determined by an insulin tolerance test. These ﬁndings
indicate that resveratrol has the potency to improve insulin sensitivity
in diet-induced obesity in rodents, and that these effects are indepen-
dent of dose and exposition time. The effect of resveratrol on insulin
sensitivity has also been tested on non-human primates. Hence,
Marchal et al. [53] performed a study with grey mouse lemurs fed a
standard diet with or without resveratrol (200mpk). Insulin sensitivity
was determined with the oral glucose tolerance test and the homeo-
stasis model assessment of insulin resistance (HOMA-IR index).
They concluded that 33 months of resveratrol supplementation
improved glucose tolerance and thereby affected insulin sensitivity
without changes in basal insulin secretion. Jimenez-Gomez et al. [54]
used male adult rhesus monkeys in their 2-year trial. Animals were
randomised in one of three groups: high-fat high-sugar diet (HFS)
with resveratrol (n = 10), HFS without resveratrol (n = 10) or a stan-
dard diet (n = 4). The dose of resveratrol was 40 mg twice a day for
the ﬁrst year, and 240 mg twice a day during the second intervention
year. Resveratrol supplementation for two years increased SIRT1 pro-
tein expression, decreased adipocyte size, and improved insulin sensi-
tivity in visceral but not subcutaneous white adipose tissue. Regarding
insulin sensitivity, an increase of insulin receptor substrate 1 protein
levels, a decrease of Akt serine 473 phosphorylation, and an increase
in the content of insulin-responsive GLUT4 glucose transporter was
measured in visceral fat depots from fasted rhesus monkeys on a HFS
diet supplemented with resveratrol as compared with animals on a
HFS diet without resveratrol supplementation. These ﬁndings from an-
imal studies led to the hypothesis that resveratrol could be a promising
anti-diabetic agent for humans.
So far, eleven clinical trials have investigated the effects of res-
veratrol on glucose homeostasis and insulin sensitivity. Three of
these studies used the gold-standard hyperinsulinemic euglycemic
clamp technique to determine insulin sensitivity [15,45,55]. Thus,
Poulsen et al. [45] supplemented healthy obese men, in a parallel-
group design, with a daily dose of 1500 mg resveratrol (n = 12) or
placebo (n = 12) for four weeks. The subjects consumed the res-
veratrol supplements in doses of 500 mg three times a day. Insulin
sensitivity was measured by hyperinsulinemic euglycemic clamp
in conjunction with 3H-labelled glucose tracer infusion. No changes
upon resveratrol supplementation were observed in endogenous glu-
cose production, oxidative glucose disposal or non-oxidative glucose
disposal. Yoshino et al. [15] also did not ﬁnd a difference in insulin sen-
sitivity in non-obese postmenopausal women who received 75 mg res-
veratrol per day. Twelve weeks of resveratrol supplementation did not
induce changes in liver, skeletal muscle or adipose tissue insulin sensi-
tivity, as measured by the hyperinsulinemic euglycemic clamp in com-
bination with stable isotope labelled tracer infusion. The third study,
by Chachay et al. [55], included 20 overweight or obese men diagnosed
with non-alcoholic fatty liver disease (NAFLD). The participants were
randomly assigned to groups given 3000 mg of resveratrol (n = 10)
or placebo (n= 10) daily for eight weeks. Also in this study resveratrol
administration did not improve insulin sensitivity, as measured by the
clamp technique.
The studies that used other measures of glucose homeostasis
or insulin sensitivity are also inconsistent in effects of resveratrol.
Timmers et al. [13] did ﬁnd positive metabolic changes in healthy
obese men (n = 11) supplemented with resveratrol. Thirty days of
resveratrol supplementation signiﬁcantly reduced blood glucose
and insulin levels and improved the HOMA-IR index compared with
the placebo condition. Crandall et al. [44] found beneﬁcial effects of
resveratrol in overweight and obese men and women with impaired
glucose tolerance. Ten subjects were enrolled in this 4-week open-
label study. Resveratrol-treatment for four weeks, with either 1.5 or
2 g per day, led to decreased peak glucose and 3-hour glucose area
under the curve following a meal. Furthermore, both 1.5 and 2 gof daily resveratrol supplementation led to an improvement of the
Matsuda index, representing improved insulin sensitivity. It must be
noted that this study did not include a placebo condition. Dash et al.
[56], who investigated overweight or obese men with mild hypertri-
glyceridemia, did not observe differences in fasting plasma glucose or
insulin levels. The participants (n= 8)were studied in two experimen-
tal conditions: after treatmentwith resveratrol and after treatmentwith
placebo in a randomised, double-blinded, crossover design. During the
resveratrol condition participants received a daily dose of 1000 mg res-
veratrol for one week, followed by a daily dose of 2000 mg resveratrol
during the second week. No signiﬁcant improvement in HOMA-IR
index was observed. One study investigated the effects of resveratrol
on HbA1c, in patients with stable coronary artery disease [57]. In total
26 male and 14 female patients were enrolled, receiving either 10 mg
resveratrol per day (n = 20) or a placebo (n = 20) for three months.
No signiﬁcant change in HbA1c was found after three months of
resveratrol-treatment compared with the baseline. Unfortunately sys-
temic conversion of resveratrol was not measured, so no statements
can bemade as towhether the low dose used (10mg)was high enough
to evoke an observable increase in resveratrol in blood plasma. Further-
more, the patients receivedmedical therapy including platelet aggrega-
tion inhibitors,β-blockers, ACE-inhibitors and statins, which could have
inﬂuenced the efﬁcacy of resveratrol. Contrary to the previously men-
tioned studies, the studies in T2D patients (without insulin treatment)
have been more consistent in reporting beneﬁcial effects of resveratrol
supplementation on blood glucose levels [46,58,59], insulin levels [46,
58], insulin resistance (deﬁned by HOMA-IR index) [46,59] and HbA1c
[43,46]. Hence, Elliott et al. [58]measured a decrease in fasting and post-
prandial glucose and insulin after a daily administration of 5 g of resver-
atrol for 28 days to T2Dpatients. Brasnyó et al. [59] performed a double-
blind, placebo-controlled trial with male T2D patients supplemented
with a dose of two times 5 mg resveratrol per day (n = 10) or placebo
(n= 9) for four weeks. Mean changes in insulin sensitivity (deﬁned by
HOMA-IR index), blood glucose and insulin were compared between
the placebo and resveratrol group. Resveratrol signiﬁcantly decreased
insulin sensitivity (deﬁned by HOMA-IR index) and decreased blood
glucose levels in T2D patients on standard oral glucose lowering medi-
cation. No difference was found in serum insulin levels between the
resveratrol and placebo groups at any time during the trial. Bhatt et al.
[43] investigated the effects of resveratrol on HbA1c in T2D patients.
Fifty-seven T2D patients, males and females combined, received a daily
dose of 250 mg resveratrol (n = 28) or received no interventional-
treatment (n = 29). The results revealed that three months of res-
veratrol supplementation signiﬁcantly improved average HbA1c in
T2D patients on oral hypoglycemic treatment (metformin and/or
glibenclamide) compared with their baseline values. A limitation of
this study is the lack of a placebo group. The fourth clinical trial in T2D
patients was executed byMovahed et al. [46]. A total of 64 T2D patients,
consisting of both males and females on standard diabetic treatment,
completed this randomised placebo-controlled double-blinded parallel
clinical trial. The intervention groupwas supplementedwith resveratrol
at a dose of 500mg twice a day (n=33), and the control group (n=31)
received placebo tablets both for a period of 45 days. Resveratrol-
treatment signiﬁcantly decreased fasting blood glucose, HbA1c, insulin
and insulin sensitivity (deﬁned by HOMA-IR index), whereas in the
placebo group fasting glucose levels increased slightly compared with
their baseline values.
To conclude, most rodent studies show a decrease in plasma
glucose [19,35,47,49,51], a decrease in plasma insulin [19,32,35,
47–49] or improved insulin sensitivity/glucose tolerance [20,32,48,
50,52] upon resveratrol administration. Clinical trials in T2D patients
imply an anti-diabetic effect of resveratrol, but the studies in non-
diabetic patients are less consistent. Studies in T2D patients investi-
gating the effects of resveratrol on insulin sensitivity by means of the
gold-standard hyperinsulinemic euglycemic clamp technique are
highly demanded.
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Excessive body weight and obesity can exert negative metabolic
health effects partly via accumulation of fat in the liver [60]. Indeed,
the increase in obesity prevalence is accompanied by an increase in
NAFLD. NAFLD itself does not explicitly evoke a risk to health but
when inﬂammation occurs and NAFLD progresses into non-alcoholic
steatohepatitis, it strongly correlates with morbidity and mortality
rates [61]. It has been suggested that resveratrol can decrease liver fat
accumulation through activation of AMPK and/or SIRT1. In the liver, de-
letion of SIRT1 leads to impaired signalling of the lipid-sensing tran-
scription factor PPARα resulting in decreased β-oxidation [62]. In
addition, knockdown of hepatic SIRT1 results in inhibition of PGC-1α
leading to increased levels of hepatic free fatty acids [63].
Sterol regulatory element-binding protein 1c (SREBP-1c) is a transcrip-
tion factor that regulates the expression of genes related to triglyceride
and fatty acid synthesis [64,65]. SIRT1 down-regulates SREBP-1c ex-
pression in the liver, leading to a decrease in lipid synthesis and fat stor-
age [64,65]. These ﬁndings lead to the idea that resveratrol could
stimulate hepatic fatty acid oxidation through AMPK/SIRT1-mediated
activation of PGC-1α and PPARα and inhibition of SREBP-1c.
Baur et al. [19] investigated resveratrol supplementation at a dose
of ~22.4 mpk in one-year oldmale C57BL/6NIAmice. Themice received
a HCD with or without resveratrol or a standard diet, for 6 months. It
was found that resveratrol prevented an increase in size and weight of
the liver as seen in the HCD group. In addition, histological staining
showed that accumulation of large lipid droplets in the liver was
present in the HCD group but not in the group on a HCD with resvera-
trol. The livers of the HCD resveratrol-treated mice also had substan-
tially more mitochondria than those of HCD animals, and were not
signiﬁcantly different from those in the standard diet group. These ﬁnd-
ings were accompanied by increased phosphorylation of AMPK and
decreased gene expression of fatty acid synthase in the liver. In a sepa-
rate cohort of the one-year-old mice on the HCD, which had been
treated with a dose of 186 mpk resveratrol for six weeks, acetylation
of PGC-1α was signiﬁcantly lower, indicating increased activity, in
resveratrol-fed animals compared with the diet matched controls.
Shang et al. [48] performed a rat study with comparable results. Male
Wistar rats fed a HFD developed abdominal obesity, NAFLD and insulin
resistance, which was considerably improved by 10 weeks of resvera-
trol supplementation (100 mpk). Again, resveratrol-treatment promot-
ed phosphorylation of AMPK in the liver, which in turn suppressed
SREBP-1c and fatty acid synthase gene expression. Another rat study
found that a low dose of resveratrol (30 mpk for six weeks) led to a
decreased accumulation of fat in the liver and activated AMPK and
PGC-1α in the male Sprague–Dawley rats [66]. However, they did not
ﬁnd a difference in mRNA expression of SREBP-1c, PPARα, SIRT1 or
PCG-1α. Poulsen et al. [67] detected that male Wistar rats treated
with 100 mg resveratrol daily for eight weeks increased hepatic mito-
chondrial content when on a HFD. In addition, hepatic uncoupling
protein 2 (UCP2) gene expressionwas signiﬁcantly increased compared
with both control and HFD-fed animals, suggesting that a resveratrol-
induced increase in mitochondrial number and UCP2 gene expression
may contribute to normalising liver fat content in HFD-induced liver
fat accumulation. Recently, Heebøll et al. [68] further reviewed the ef-
fects of resveratrol on experimental and clinical NAFLD. They concluded
that rodent studies demonstrate a consistent decrease in cholesterol ac-
cumulation [35,69–74], hepatic triglycerides [35,47,66,69,70,72,75–79]
and liver weight [19,48,70,73,76,77]. Also, several other improvements
in liver fat content and anatomy were reported in rodents after resver-
atrol supplementation [19,48–50,67,69–72,74,76–82]. For example, im-
provementswere noted regarding steatosis, steatohepatitis and ﬁbrosis.
Taken together, resveratrol in rodents is at least partly able to prevent
liver fat accumulation induced by HFD or HCD, probably via increasing
fatty acid oxidation and decreasing lipogenesis. These effects could be
mediated by activation of the AMPK–SIRT1 axis.To date, only four clinical trials have been performed investigating
effects of resveratrol on liver fat accumulation. One of these studies spe-
ciﬁcally focussed on patients suffering from NAFLD, whilst the other
three studies involved healthy participants. In the study by Chachay
et al. [55] 10 NAFLD patients received a daily dose of 3000 mg resvera-
trol and another group of 10 NAFLD patients received a placebo. One of
the study outcomes was hepatic steatosis assessed by magnetic
resonance spectroscopy (MRS) and imaging (MRI). Chachay et al. [55]
concluded that eight weeks of resveratrol administration did not sig-
niﬁcantly improve any features of NAFLD, compared with placebo.
Furthermore, based on increases in liver enzymes ALT and AST, they
concluded that there was an increase in hepatic stress in the resveratrol
group. Timmers et al. [13] used a much lower dose of resveratrol for
a shorter period of time: 150 mg/d, for 30 days. The outcome of this
study was that resveratrol supplementation led to a reduction in liver
fat in healthy obese males, measured by MRS. In addition, a signiﬁcant
reduction in liver transaminases (ALT) was found suggesting beneﬁcial
effects of resveratrol on liver function. In contrast, Poulsen et al. [45],
who also investigated healthy obese males, did not ﬁnd effects of res-
veratrol (1500 mg/d) on liver fat content (measured by MRS) or liver
transaminase levels after four weeks of supplementation. The fourth
clinical trial, in non-obese postmenopausal women, also did not ﬁnd
signiﬁcant differences in liver fat (measured by MRS) after 12 weeks
of supplementation (75 mg/d) [15]. Taken together; although rodent
studies have generally found a lowering effect of resveratrol on liver
fat content, human studies have so far been less consistent. Again, dif-
ferences in doses used or duration of resveratrol treatmentmay explain
differences between human studies so far, andmore clinical studies are
required.
7. Discussion and future studies
The effect of resveratrol on metabolic health has received much at-
tention in the last decade. Pre-clinical studies have revealed promising
results regarding beneﬁcial effects of resveratrol on preventing and re-
versing obesity-induced metabolic disturbances. Speciﬁcally, beneﬁcial
effects have been observed in rodents supplemented with resveratrol
with respect to mitochondrial function, insulin sensitivity and liver fat
accumulation. These effects can be attributed to activation of the
AMPK–SIRT1–PGC-1α axis. Clinical trials performed so far have been
less consistent. This inconsistency can most likely be explained by dif-
ferences in duration and dose of resveratrol used between studies. Rel-
ative to animal studies, clinical trials used low doses of resveratrol. For
example, a dose of 400 mpk is frequently used in rodents and would
translate into a dose of 30 g resveratrol per day for an average human
with a body weight of 75 kg. Despite using lower doses of resveratrol
in human clinical trials, plasma resveratrol concentrations have been
found comparable to those found inmice studies [13]. However, a direct
comparison of circulating levels between animals and humans may be
difﬁcult as in vivo metabolism of resveratrol might differ between
mice and humans. Human studies would be needed to determine the
optimal dose of resveratrol to activate the AMPK–SIRT1 axis. In fact
only few human studies so far have determined if resveratrol adminis-
tration indeed resulted in activation of the AMPK–SIRT1 axis, leaving
the possibility that suboptimal doses have been used so far. In addition,
long-term studies in humans are needed to investigate the possibility of
cumulative effects of resveratrol on metabolic health. Finally, it is im-
portant to note that the effects of resveratrol are mainly observed in an-
imals fed a HFD or HCD diet, implying that resveratrol is particularly
potent in reversing early stage metabolic disorders. The same could
apply to humans, which is supported by the fact that so far only clinical
trials in overweight/obese participants [13,44] or T2D patients [43,46,
58,59] have found beneﬁcial effects.
An interesting new venue for future research would be a focus on
human BAT and so-called browning of white adipose tissue. In contrast
to white adipose tissue, BAT stores little fat and instead burns fat to
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the hypothesis that stimulating BAT thermogenesis could initiate
weight loss [83]. A few animal studies have been performed investigat-
ing potential effects of resveratrol on BAT thermogenesis and these
studies were overall encouraging, indicating enhanced mitochondrial
biogenesis [32], induction of UCP1 [32,39,40] and activation of BMP7
[40] (a promoter of brown preadipocyte differentiation) in BAT. Given
the interest in the physiology of human BAT, it would be interesting to
investigate if resveratrol can also activate BAT in humans.
To conclude, even though data from animal studies look promising,
currently the number of clinical trials is too limited to make any ﬁrm
statements regarding the effects of resveratrol on obesity-induced neg-
ative health outcomes in humans. More speciﬁcally, future research
should primarily focus on dose, efﬁcacy and chronic exposure effects
of resveratrol. Finally, human intervention studies are necessary focus-
ing on the potential of resveratrol to stimulate BAT thermogenesis.Acknowledgements
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